PMID- 34538843
OWN - NLM
STAT- MEDLINE
DCOM- 20220419
LR  - 20230818
IS  - 1872-6623 (Electronic)
IS  - 0304-3959 (Print)
IS  - 0304-3959 (Linking)
VI  - 163
IP  - 5
DP  - 2022 May 1
TI  - Sex differences in medical cannabis-related adverse effects.
PG  - 975-983
LID - 10.1097/j.pain.0000000000002463 [doi]
AB  - Studies have shown that women are more susceptible to adverse effects (AEs) from 
      conventional drugs. This study aimed to investigate the differences of medical 
      cannabis (MC)-related AEs between women and men in patients with chronic 
      noncancer pain (CNCP). This is a cross-sectional study of adult patients licensed 
      for MC treatment who were also diagnosed as patients with CNCP by a physician. 
      Data included self-reported questionnaires and comprehensive MC treatment 
      information. Simultaneously, identification and quantification of 
      phytocannabinoids and terpenoids from the MC cultivars were performed. 
      Comparative statistics were used to evaluate differences between men and women. 
      Four hundred twenty-nine patients with CNCP (64% males) reported fully on their 
      MC treatment. Subgrouping by sex demonstrated that the weight-adjusted doses were 
      similar between men and women (0.48 [0.33-0.6] gr for men and 0.47 [0.34-0.66] gr 
      for women). Nonetheless, women reported more than men on MC-related AEs. Further 
      analysis revealed that women consumed different MC cultivar combinations than 
      men, with significantly higher monthly doses of the phytocannabinoids CBD and CBC 
      and significantly lower monthly doses of the phytocannabinoid 373-15c and the 
      terpenoid linalool. Our findings demonstrate sex differences in MC-related AEs 
      among patients with CNCP. Women are more susceptible to MC-related AEs, 
      presumably because of both the inherent sex effect and the consumption of 
      specific phytocannabinoid compositions in the MC cultivar(s). The understanding 
      of these differences may be crucial for planning MC treatments with safer 
      phytocannabinoid and terpenoid compositions and to better inform patients of 
      expected AEs.
CI  - Copyright (c) 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on 
      behalf of the International Association for the Study of Pain.
FAU - Aviram, Joshua
AU  - Aviram J
AUID- ORCID: 0000-0003-2075-5446
AD  - Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel.
FAU - Lewitus, Gil M
AU  - Lewitus GM
AUID- ORCID: 0000-0001-8696-8677
FAU - Vysotski, Yelena
AU  - Vysotski Y
FAU - Berman, Paula
AU  - Berman P
AUID- ORCID: 0000-0002-6821-3307
FAU - Shapira, Anna
AU  - Shapira A
FAU - Procaccia, Shiri
AU  - Procaccia S
FAU - Meiri, David
AU  - Meiri D
AUID- ORCID: 0000-0001-7627-1569
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pain
JT  - Pain
JID - 7508686
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Medical Marijuana)
RN  - 0 (Terpenes)
SB  - IM
CIN - Pain. 2022 Dec 1;163(12):e1219-e1220. PMID: 36383424
MH  - Adult
MH  - Analgesics, Opioid/therapeutic use
MH  - *Chronic Pain/drug therapy
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - *Medical Marijuana/adverse effects
MH  - Sex Characteristics
MH  - Terpenes/therapeutic use
PMC - PMC9009319
COIS- The authors have no conflicts of interest to declare.
EDAT- 2021/09/21 06:00
MHDA- 2022/04/20 06:00
PMCR- 2022/04/14
CRDT- 2021/09/20 05:50
PHST- 2021/05/11 00:00 [received]
PHST- 2021/08/18 00:00 [accepted]
PHST- 2021/09/21 06:00 [pubmed]
PHST- 2022/04/20 06:00 [medline]
PHST- 2021/09/20 05:50 [entrez]
PHST- 2022/04/14 00:00 [pmc-release]
AID - 00006396-202205000-00025 [pii]
AID - PAIN-D-21-00521 [pii]
AID - 10.1097/j.pain.0000000000002463 [doi]
PST - ppublish
SO  - Pain. 2022 May 1;163(5):975-983. doi: 10.1097/j.pain.0000000000002463.